Clinical Scorecard: Daily Fluctuations in Heart Rate Variability Monitored by Wearable Devices in the Chronic Renal Insufficiency Cohort Study
At a Glance
Category
Detail
Condition
Chronic Kidney Disease (CKD) with cardiovascular risk
Key Mechanisms
Heart rate variability (HRV) as a marker of autonomic function influenced by diabetes, proteinuria, and circadian rhythms
Target Population
Adults with chronic kidney disease, including those with diabetes and cardiovascular disease
Care Setting
Out-of-clinic, ambulatory monitoring using wearable EKG devices
Key Highlights
Continuous wearable EKG monitoring over ~50 hours in 458 CKD participants demonstrated feasibility and provided detailed HRV data.
Diabetes and higher proteinuria levels were significantly associated with lower SDNN, indicating reduced heart rate variability and higher cardiovascular risk.
Time-specific HRV metrics may serve as predictive biomarkers for cardiovascular outcomes in CKD, supporting personalized risk stratification.
Guideline-Based Recommendations
Diagnosis
Use wearable EKG devices to obtain continuous HRV measurements in CKD patients for cardiovascular risk assessment.
Assess SDNN as a key HRV metric, with values ≤33.7 ms indicating low HRV and increased cardiovascular risk.
Management
Monitor and manage diabetes and proteinuria aggressively to potentially improve HRV and reduce cardiovascular risk in CKD.
Incorporate time-of-day variability in HRV into clinical evaluations to identify high-risk CKD subgroups.
Monitoring & Follow-up
Implement multi-day continuous HRV monitoring using wearable devices to capture diurnal fluctuations and disease burden.
Regularly evaluate HRV changes in relation to clinical and demographic factors such as diabetes status and proteinuria levels.
Risks
Low HRV (reduced SDNN) is associated with higher cardiovascular morbidity and mortality in CKD patients.
Absence of circadian rhythmicity in cardiovascular parameters correlates with increased risk of cardiovascular death.
Patient & Prescribing Data
CKD patients with and without diabetes and cardiovascular disease
Diabetic CKD patients and those with higher proteinuria exhibit lower HRV, suggesting a need for targeted interventions to mitigate cardiovascular risk.
Clinical Best Practices
Utilize wearable EKG technology for out-of-clinic, real-world HRV monitoring in CKD patients.
Interpret HRV metrics such as SDNN in the context of patient-specific factors including diabetes and proteinuria.
Incorporate circadian rhythm analysis into cardiovascular risk stratification protocols for CKD.
Recognize low HRV as a marker for increased cardiovascular risk and consider intensified monitoring and management.
by Carsten Skarke, Wei Yang, Daohang Sha, Nicholas F. Lahens, Tamara Isakova, Mark Unruh, Rajat Deo, Eunice Carmona-Powell, John H. Holmes, Elaine Ficarra, Jing Chen, Jiang He, Hernan Rincon-Choles, Vallabh Shah, Chi-yuan Hsu, Amanda H. Anderson, James P. Lash, Mahboob Rahman
